WO2008137009A1 - Liquorice extract antimicrobial and anti-inflammatory isolates - Google Patents
Liquorice extract antimicrobial and anti-inflammatory isolates Download PDFInfo
- Publication number
- WO2008137009A1 WO2008137009A1 PCT/US2008/005578 US2008005578W WO2008137009A1 WO 2008137009 A1 WO2008137009 A1 WO 2008137009A1 US 2008005578 W US2008005578 W US 2008005578W WO 2008137009 A1 WO2008137009 A1 WO 2008137009A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- extract
- care composition
- oral care
- licorisoflavan
- licoricidin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Definitions
- Extracts from the root of plants of the genus Glycyrrhiza are used for flavorings, the extract imparting the flavor of licorice (liquorice), among other purposes.
- Current extraction methods use a hot water extraction method. This method preferentially isolates hydrophilic components of the plant root.
- the major single component isolated with the prior art extraction methods is glycyrrhizic acid. Glycyrrhizic acid is used predominately as a sweetener and a flavoring.
- Prior art extraction methods remove little or none of the hydrophobic or lipophilic components of the plant root.
- the present invention provides, in one aspect, novel and non-obvious methods of producing extracts from the roots of Glycyrrhiza sp.
- the method of extraction of the present invention comprises utilizing a supercritical CO 2 extraction process. Details of the process of the present invention are given below in the Description of the Preferred Embodiments.
- the methods of the present invention solve the problems of the prior art extraction methods by greatly reducing or eliminating the need for organic solvents during the extraction process and providing an extract that is rich in prenylated flavonoids (e.g., isoflavans, isoflavonol, flavanone, isoflavone) while also being virtually void or void of glycyrrhizic acid (e.g., with no detectable glycyrrhizic acid).
- the methods of the present invention also extract lipophilic components while extracting very little of the hydrophilic components.
- the method of the present invention also greatly reduces or eliminates the production of a waste water stream as a result of the extraction process.
- the present invention further relates to the extracts made from the extraction processes of the present invention.
- the extract of the present invention comprises an extract from G. uralensis comprising predominately licoricidin and licorisoflavan A (5-O-methyllicoricidin) as the lipophilic components.
- Both, licoricidin and licorisoflavan A are prenylated isoflavans, a particular type of flavonoids.
- the extract of the present invention is isolated without using ethanol as a modifier during the extraction process.
- the concentration ranges of licoricidin and licorisoflavan A are approximately 0.5 - 6.0 % for both.
- the extract of the present invention is produced using ethanol as a modifier during the extraction process.
- the concentration ranges of licoricidin and licorisoflavan A are approximately 2.0 - 20.0 % for licoricidin and 1.0 - 8.0 % for licorisoflavan A .
- the concentration of glycyrrhizic acid in the extracts is less than 0.10 %. In yet another embodiment, the concentration of glycyrrhizic acid in the extracts is less than 0.01 % or 0.001 %. Furthermore, the supercritical CO 2 extracts of the present invention also comprises significant amounts of fatty acids (plamitic and linoleic acids, in particular, for example).
- licoricidin and licorisoflavan A provide the greatest level of anti-microbial effect.
- the present invention contemplates oral and body care compositions that comprise amounts of licoricidin and licorisoflavan A effective in providing antimicrobial and anti-inflammatory effects.
- Glycyrrhiza provides extracts wherein the predominant lipophilic components are prenylated flavonoids although the exact prenylated flavonoids may differ.
- an extract of G. glabra made by the extraction process of the present invention would have as the major prenylated flavonoids, glabridin, methylglabridin and glabrol.
- the ethanol is at a concentration of between approximately 2.0 and 10 %.
- the ethanol modifier is between approximately 4.0 and 6.0 %.
- the use of ethanol is not necessary to produce the extracts of the present invention. Ethanol helps to extract highest amount of compounds which have less lipophilic properties than using CO 2 alone.
- the present invention also relates to products that are made from said extracts.
- the extract is used in an oral care product.
- suitable oral care products in which the extract of the present invention can be used include, but are not limited to, dentifrices (e.g., toothpaste, toothpaste gels, toothpowders, denture cleaning agents and compounds, mouthwashes and mouth rinses, toothpicks, dental floss, chewing gums, pastilles, lozenges, dissolvable tablets, chewable tablets, etc.).
- the extracts of the present invention may be used in body care products such as, but not limited to, skin creams, skin lotions, sun screen compositions, soaps, baby care products, shaving products, deodorants, shampoos, etc.
- Figure 1 shows a HPLC chromatogram of extracts of Glycyrrhiza uralensis generated with A) hot water extraction, B) ethanol extraction, C) ethyl acetate extraction, D) Supercritical CO 2 extraction and E) Supercritical CO 2 extraction with ethanol as a modifier.
- the present invention relates to extracts from Glycyrrhiza sp. that have less environmental impact than prior art extraction methods and that extract a greater percentage of the lipophilic components while extracting fewer hydrophilic components than the prior art methods.
- the present invention also relates to uses for the extracts of the present invention.
- the present invention relates to an extraction process of Glycyrrhiza sp. that utilizes a supercritical CO 2 extraction process.
- Extracts may be made from the root of many different species of legume- like plants from the genus Glycyrrhiza and more particularly from the species Glycyrrhiza uralensis.
- the plants are native to southern Europe and parts of Asia.
- G. uralensis is used extensively in traditional Chinese medicine. Still, the present invention is not limited to any specific plant source.
- Glycyrrhiza from which extracts my be made thorough the processes of the present invention include, but are not limited to, Glycyrrhiza acanthocarpa, Glycyrrhiza aspera, Glycyrrhiza astragalina, Glycyrrhiza bucharica, Glycyrrhiza echinata, Glycyrrhiza eglandulosa, Glycyrrhiza foetida, Glycyrrhiza foetidissima, Glycyrrhiza glabra, Glycyrrhiza gontscharovii, Glycyrrhiza iconica, Glycyrrhiza korshinskyi, Glycyrrhiza lepidota, Glycyrrhiza pallidiflora, Glycyrrhiza squamulosa, Glycyr
- the extracts of the present invention are unlike prior art extracts of Glycyrrhiza sp.
- the extracts of the present invention are high in the compounds known as prenylated flavonoids (e.g., licoricidin and licorisoflavan A). Both of these compounds have anti-inflammatory, antibacterial, anti-adherent and anti-fungal effects.
- the extract of the present invention has been shown to have significant antibacterial activity against gram-positive bacteria such as Staphylococcus aureus and Streptocuccus mutans, gram-negative anaerobic bacteria like Porphyromonas gingivalis and Prevotella intermedia as well as antifungal activity against Aspergillus niger.
- the extracts of the present invention are void or virtually void of glycyrrhizic acid when examined by high pressure liquid chromatography (HPLC) (see, Experimental Section, below).
- HPLC high pressure liquid chromatography
- Glycyrrhizic acid has been used a sweetener and flavor in the prior art and is not needed in the compositions of the present invention.
- Licoricidin and licorisoflavan A are two of the components of the supercritical CO 2 extract of the present invention. They both showed antimicrobial activity (MIC) on Streptococcus mutans at 3.125 ⁇ g/ml, the principal causal agent of carries, and against Prevotella interrmedia at about 0.78 ⁇ g/ml and about 1.56 ⁇ g /ml for licoricidin and licorisoflavan A, respectively and against Porphyromonas gingivalis at 0.39 ⁇ g /ml and 0.78 ⁇ g /ml for licoricidin and licorisoflavan A, respectively.
- MIC antimicrobial activity
- the extract produced by the process of the present invention can be used in many products including oral care products and body care products for their anti-inflammatory, antibacterial, anti-adherent and antifungal properties. Below, we describe some of the products suitable for use with the extract of the present invention.
- the Glycyrrhiza sp root (i.e., licorice extract) of the present invention may be formulated in a dental floss.
- the extracts of the present invention may be impregnated within dental floss so that it comes into contact with the user's teeth during flossing.
- Concentrations of the extract of the present invention when used in a dental floss composition are about 0.1 to 5.0 % by weight of the wax mixture used in coating the floss material.
- Preferred concentrations are about 0.5 to 3.0 % by weight of the wax mixture used in coating the floss material.
- Dental floss may be used to ensure that the extracts of the present invention come into contact with the surfaces of the teeth that face each other and are hard to reach by some of the other means described.
- licoricidin and licorisoflavan A are used as the antimicrobial agents in the floss of the present invention they can be used alone or in a mixture at total concentrations of about 0.01 wt % to 1.0 wt %, at total concentrations of about 0.05 wt % to 0.5 wt % or at total concentrations of about 0.1 wt % to 0.2 wt %.
- said dental floss is made as discussed below.
- One skilled in the art will realize that there are other methods and compositions for the manufacture of dental floss that are compatible with the licorice-based composition of the present invention.
- dental floss(es) shall be herein understood to include both dental flosses and dental tapes as well as any other similar article.
- the dental flosses and tapes used in the present invention may include any suitable or commercially available dental floss or tape.
- These flosses and tapes can be fabricated from either natural or synthetic sources examples of which include, but are not limited to, filaments or yarns of high and normal tenacity polymers, GoreTexTM, nylons, polyolefins, polyethylenes, polypropylenes, fluorocarbon compounds, polytetrafluoroethylenes, rayons, dacrons, acrylics, acetate polymers, and other plastics alone or in combination.
- Natural substances may include, but are not limited to, cotton, wool, silk, linen, hemp, soy and other staple fibers alone or in combination. Blends of synthetic-natural fibers can also be used. However, synthetic filaments tend to fray less than natural fibers.
- the tensile strength of floss must be evenly distributed along their length. This is the key with fibers - they will break at their weakest point, so even keeled tensile strength is the key.
- the dental floss of the present invention is related to fibers with high tensile strength while still being usable for cleaning between teeth.
- the denier of a floss or floss fiber measures it's weight and also to tensile strength. Denier is defined as the weight of 9,000 meters of uncoated floss in grams.
- the denier of round floss is about 750 to 950 and for flat floss it is about 950 to 1150.
- the length, diameter, structure or design of the floss itself is also not limited to any specific size, shape, arrangement or configuration and, thus, can be fabricated to suite any specific intention. It can, for example, be composed of a plurality of individual filaments that have been formed together to give a larger thread having a sufficiently small diameter to permit insertion between the teeth. It can also comprise a composite multifilament yarn bonded to an extruded monofilament or to another multifilament yarn. A single circular, square or rectangular shaped monofilament thread is also useful. Other suitable variations are also well known in the art and as such are also useable in the invention disclosed herein.
- Binders are used in the invention disclosed herein to bind or otherwise attach to a dental floss the ingredients herein specified by this disclosure. They also provide the ability to alter the frictional characteristics of dental floss as well as help bind together the individual filaments comprising the floss itself. Moreover, the varieties used herein are not restricted to any specific types or compositions and are thus, given great freedom in their formulations, structures or make-ups.
- binders may therefore include, but are not limited to, natural waxes from plants (e.g., carnauba wax, soy wax and jojoba wax) as well as other water soluble or non-water soluble wax or wax-like compounds or water soluble or non-water soluble polymers, soaps, gums, resins (e.g., myrrh and propolis) and other substances known in the art.
- plants e.g., carnauba wax, soy wax and jojoba wax
- other water soluble or non-water soluble wax or wax-like compounds or water soluble or non-water soluble polymers soaps, gums, resins (e.g., myrrh and propolis) and other substances known in the art.
- Flosses may also make use of, for example, one or more solubilizing agents. Their function, as such, will be to aid in dissociation. Suitable solubilizing agents may therefore include, but are not limited to, filtered water, reverse osmosis water, distilled water and deionized water, alone or in combination. However, deionized water has been found preferable to the others.
- Flosses may also utilize, for example, one or more flavoring agents.
- These preferably comprise oils or extracts derived from plants and fruits such as citrus oils, fruit essences, mint, peppermint oil, spearmint oil, clove oil, oil of wintergreen, anise, sassafras, sage, eucalyptus, marjoram, cinnamon, lemon, orange, banana, cherry, fennel, apple, pineapple, grape, strawberry and blueberry.
- oils or extracts derived from plants and fruits such as citrus oils, fruit essences, mint, peppermint oil, spearmint oil, clove oil, oil of wintergreen, anise, sassafras, sage, eucalyptus, marjoram, cinnamon, lemon, orange, banana, cherry, fennel, apple, pineapple, grape, strawberry and blueberry.
- Those skilled in the art will recognize that such natural flavoring agents may be used independently or combined in any sensorially acceptable blend. All such flavors and flavor blends
- flosses may also contain, for example, one or more natural sweetening agents. These may include, but are not limited to, xylitol, glycerol, sorbitol, maltitol, erythritol, sucrose, lactose, dextrose, maltose, dextrin, fructose, galactose and the like.
- Fluorides have in the past been found to help prevent the incidence of carious lesions or caries.
- Caries are caused when teeth demineralize at a rate faster than they remineralize and most demineralization is caused by acid producing dental plaques. Remineralization, however, is promoted by calcium and phosphate, the chief remineralizing agents found also in saliva. Fluoride based compounds, therefore, provide protection from carious lesions or caries by acting as a catalyst to speed the precipitation of calcium phosphate, in the form of a hydroxy apatite, onto or into teeth. However, this is not fluoride's only role.
- flosses may contain, for example, one or more fluoride based compounds. These compounds may also be slightly soluble in water or may be fully water soluble. They are, however, foremost characterized by their ability to release fluoride ions in water and their freedom from undesired reactions with the floss's other compounds.
- fluoride-based compounds which can comprise inorganic fluoride salts such as soluble alkali metal, alkaline earth metal salts, and others. When a fluoride compound is employed, the amount used is dependent to a large extent upon the type of fluorine compound, its solubility, and the final formulation and structure selected.
- the licorice supercritical CO 2 extracts (Glycyrrhiza sp root extract) of the present invention may also be used with toothpastes, tooth gels and tooth powders.
- the concentration of the extract of the present invention used in dentifrices ranges from about 0.002 to 2.0 % by weight. In a preferred concentration the range is between 0.02 to 1.0 % by weight.
- licoricidin and licorisoflavan A are used as the antimicrobial agents in the dentifrice of the present invention they can be used alone or in a mixture at total concentrations of about 0.01 wt % to 1.0 wt %, at total concentrations of about 0.05 wt % to 0.5 wt % or at total concentrations of about 0.1 wt % to 0.2 wt %.
- compositions in the form of toothpastes, gels, liquid gels, denture cleansing liquids and pastes, and the like will generally comprise a binder or thickening agent.
- Binders suitable for use herein include carrageenan (preferred) and/or natural gums such as gum karaya, xanthan gum (preferred), gum arabic (preferred) and gum tragacanth can also be used, as well as other agents known in the art.
- Colloidal magnesium aluminium silicate or finely divided hydrated silica can be used as part of the thickening agent to further improve texture.
- Binders/thickening agents can be used in an amount from about 0.1% to about 15.0 %, preferably from about 1.0 to about 12 % by weight of the total composition.
- the actives are fluoride and potassium nitrate, their level are described in their respective FDA monographs for anti-cavity and sensitivity. Active for gingivitis are still pending the finalization of the monograph.
- the abrasives are calcium carbonate, baking soda or hydrated silica.
- compositions will typically comprise one or more sweeteners and flavorings.
- suitable sweeteners and flavorings for use in dentifrices are discussed above.
- pH balancing agents e.g., citric acid, NaOH
- surfactants e.g., sodium lauryl sulfate
- preservatives e.g., benzoic acid, sorbic acid
- the compositions of the present invention may include botanicals as well.
- licorice extract of the present invention there may also be included in the dentifrice minor amounts, e.g., 0.01 to 2 % by weight of other natural ingredients such as antioxidants, preservatives, pH adjusting agents, desensitizing agents, stabilizing agents, gelling agents, flavors, etc.
- a preferred gelling or binding agent is one or more of carrageenan or xanthan gum.
- Preferred flavorings are natural flavorings such as peppermint, spearmint, apricot and cinnamon, etc.
- the formulation may contain an agent for relieving pain in people with sensitive teeth.
- a preferred ingredient for this purpose is potassium nitrate.
- Dispersing agents may be used in the present invention. Preferred dispersants are sodium lauryl sulfate or saponin containing plant extracts.
- humectants moisture retaining agent
- humectants moisture retaining agent
- Preferred humectants are glycerin and sorbitol.
- Certain humectants can also impart a desirable sweetness to toothpaste compositions.
- Liquid dentifrice and mouthwashes can also contain a quantity of humectants. Suitable humectants are well known in the art. When present, humectants generally represent from about 10 % to about 70 %, by weight of the compositions of the invention.
- Toothpowders may make use of many of the same ingredients as toothpastes except that they must be mixed in a dried state (i.e., dry milled) or mixed as a liquid composition and then dried via, for example, various known spray drying techniques. Spray drying is described as when a liquid form of a composition is sprayed as a mist into a hot, dry chamber wherein the aqueous portion of the mist is evaporated by the dry heat of the chamber leaving only the dry constituents of the composition in a powdered form. The powdered form of the composition has a moisture content of between about 0.1 % to 5 %. Toothpowders then rehydrate upon use either by the addition of water (e.g., with water applied by the user) at the time of use or by the user's saliva.
- water e.g., with water applied by the user
- Another aspect of the present invention is dissolvable denture cleaning tablet comprising the Glycyrrhiza sp. supercritical CO 2 extract of the present invention. Still another aspect of the present invention is a dissolvable denture cleaning tablet comprising one or both of licoricidin and licorisoflavan A isolated, for example, from the supercritical CO 2 extract of the present invention.
- Such tablets may be solid, layered, have a liquid filled center, etc.
- the tablet should dissolve completely or nearly completely in an aqueous solution in less than about one hour and, preferably, in less than about 15 minutes.
- the tablet may be effervescent but need not be.
- Water-soluble, denture cleanser tablets are made by first preparing and drying a granulation of ingredients using a suitable binder in an, for example, anhydrous alcohol solution. The resulting granular mixture is then dried to a moisture content of 0.4% or less, screened, and then thoroughly blended with the desired active ingredients along with binders, fillers, extenders, dyes, flavors, lubricants and the like in a suitable blending apparatus. The final blends are fed into a punch and die tableting press where it is compacted into tablets. Thereafter the tablets so formed are released and packaged.
- a suitable binder in an, for example, anhydrous alcohol solution.
- the resulting granular mixture is then dried to a moisture content of 0.4% or less, screened, and then thoroughly blended with the desired active ingredients along with binders, fillers, extenders, dyes, flavors, lubricants and the like in a suitable blending apparatus.
- the final blends are fed into a punch and die tableting press where it is compacted into tablets.
- the mouthwashes and rinses of the present invention comprise the Glycyrrhiza sp. supercritical CO 2 extract of the present invention in, for example, a water/glycerin solution and may additionally comprise one or more of flavor, humectant, sweetener, emulsifier (e.g.,poloxamer) and colorant.
- a mouthwash comprising one or both of licoricidin and licorisoflavan A isolated, for example, from the supercritical CO 2 extract of the present invention.
- Mouthwashes can include glycerin at a level of from 0 to 60 %, preferably from 0 to 30 % by weight.
- the pH value of such mouthwash preparations is generally from about 3.5 to about 8.0 and preferably from about 4.0 to about 7.5. A pH greater than 8.7 would result in an unpleasant mouth feel.
- the oral liquid preparations may also contain surface active agents, i.e., surfactants, in amounts up to about 5.0 % and more preferably between about 0.5 to 2.0 %; and fluoride- providing compounds in amounts up to about 2.0 % by weight of the preparation and more preferably about 0.0442% for sodium fluoride or 0.025% of the fluoride ion.
- the mouthwashes and mouth rinses of the present invention may also comprise one or more alcohols.
- alcohols for example, ethanol.
- the chewing gum compositions that comprises the Glycyrrhiza sp. supercritical CO 2 extract of the present invention may be in the form of a conventional chewing gum or any other product form which is suitable for chewing.
- Still another aspect of the present invention is a chewing gum comprising one or both of licoricidin and licorisoflavan A isolated from the supercritical CO 2 extract of the present invention. Suitable physical forms include sticks, squares and dragees (i.e., sugar coated gum; e.g., Chiclets TM).
- the chewing gum may also have a liquid-filled center wherein the liquid center contains the licorice-based compositions (See, e.g., U.S. Patent number 6,280,780).
- the chewing gum may also be a digestible or dissolvable gum suitable for chewing.
- a chewing gum is typically retained in the oral cavity for a time sufficient to allow ingredients released to contact substantially all of the dental surfaces and/or oral tissues for purposes of oral activity.
- carrier materials means any safe and effective additional chewing gum components used in the chewing gum compositions of the present invention.
- Such materials include elastomers, resins, plasticisers, fats, solvents, waxes, emulsifiers, softeners, bulking agents, sweeteners, absorbents, orally active metallic ions, cationic material, fluoride ion sources, additional anticalculus agents, antimicrobial agents, buffers, whitening agents, alkali metal bicarbonate salts, thickening materials, humectants, water, surfactants, titanium dioxide, flavoring agents, xylitol, coloring agents and mixtures thereof.
- the chewing gum of the present invention is manufactured by methods known in the art. For example, the gum base is heated to 45° C to soften. The mixer vessel is maintained at 45° C during entire mixing process and additives as described herein as well as the extract of the present invention are added and mixed to homogeneity. Then the gum mixture is formed into sticks, squares, etc., wrapped and cooled. If desired, the gum is coated in a sugar or sugar-free candy coating.
- the licorice composition may also be used in lozenge and pastille compositions.
- the carrier for the lozenges and pastilles is conveniently a sugar, such as glucose, lactose or sucrose, or a substantially non-cariogenic material, for example mannitol, xylitol, maltitol, erythritol or sorbitol.
- the lozenges preferably contain one or more binders, such as gelatin (a vegetal gum, e.g., Arabic gum, is preferred) or liquid glucose BPC 1963, which in total may conveniently be present in an amount of from about 0.5 to 10 % weight of the lozenge. A preferred range is from about 1 to 5 % by weight.
- binders such as gelatin (a vegetal gum, e.g., Arabic gum, is preferred) or liquid glucose BPC 1963, which in total may conveniently be present in an amount of from about 0.5 to 10 % weight of the lozenge. A preferred range is from about 1 to 5 % by weight.
- the lozenges may additionally contain a lubricant, such as stearic acid or a stearate such as magnesium stearate to facilitate manufacture of the lozenge.
- a lubricant such as stearic acid or a stearate such as magnesium stearate to facilitate manufacture of the lozenge.
- the total content thereof in the lozenge is preferably from 0.1 to 5 % by weight.
- the lozenges may be prepared by conventional lozenge making procedures, for example by admixing the 1 ,3-bis(2-carboxychromon-5-yloxy)-2- hydroxypropane or salt thereof with the adjuvant, diluent or carrier and compressing the mixture.
- the bis-chromone and the adjuvant, diluent or carrier are desirably first granulated together before being compressed into the lozenge.
- the granulation step is preferably a wet granulation step, and a lubricant is desirably added immediately before the compression step.
- Pastilles are a hard, jelly- like preparation made from a mixture of glycerin, gelatin (or other natural gelifying) and water, to which the extract of the present invention is incorporated. Flavor may be added too.
- the glyco-gelatin base may be melted by gentle heating and any ingredients added. The warmed base is then poured into moulds and allowed to set. For example, See, www.rpsgb.org.uk/pdfs/mussheet04.pdf.
- Typical body care products include, for example, body lotions, skin creams, soaps, hair care products (for example, shampoos and conditioners), sun screens, anti-inflammatory topical agents, depilatory compositions, shaving products (for example, shaving cream and aftershave lotions), deodorant, baby care, etc.
- Body care products are products used on the external body (e.g., skin, hair, etc.) as, usually, topical treatments.
- U.S. Patent No. 6,861 ,062 to Silva, et a/. discloses exemplary formulations and methods for making skin creams.
- Herbal compositions for skin care products are also known in the art (see, e.g., U.S. Patent No. 6,586,018 to Fasano, which is incorporated herein by reference) discloses exemplary formulations and methods of manufacture.
- compositions and methods of producing shaving products are also known in the art.
- U.S. Patent No. 7,179,454 to Lucas which is herein incorporated by reference, discloses several exemplary formulations and methods of manufacture.
- U.S. Patent No. 6,479,043 to Tietjen, et a/. (incorporated herein by reference) discloses exemplary formulations and methods of manufacture for depilatory agents.
- Body care products of the present invention comprise an extract of the root of the plant Glycyrrhiza sp., comprising an essentially glycyrrhizic acid free extract wherein the major components of the extract are prenylated flavonoids and wherein the root was extracted by a supercritical CO ⁇ extraction process.
- the extract is from Glycyrrhiza uralensis and the major components of the extract are licoricidin and licorisoflavan A.
- the extract is from extract is from Glycyrrhiza glabra and the major component of the extract is glabridin.
- a deodorant of the present invention in one embodiment, comprises an extract of of the present invention in combination with an antioxidant compound, preferably with an ingredient from the group of tocopherol and its derivatives, butyl hydroxyanisole (BHA), butyl hydroxytoluene (BHT), erythorbic acid, propyl gallate, sodium erythorbate, tertiary butyl hydroquinone (TBHQ), and rosemary extract, more preferably with ascorbic acid and salts thereof.
- the deodorant may comprises certain metal salts of an unsaturated hydroxy carboxylic acid, preferably zinc ricinoleate.
- the extract of the present invention is at a concentration of about 0.01 to 5.0 % by weight and in a more preferred embodiment, from about 0.05 to 2.0 % by weight.
- licoricidin and licorisoflavan A are used as the antimicrobial agents in the deodorant of the present invention they can be used alone or in a mixture at total concentrations of about 0.01 wt % to 1.0 wt %, at total concentrations of about 0.05 wt % to 0.5 wt % or at total concentrations of about 0.1 wt % to 0.2 wt %.
- the concentration of the extracts of the present invention are at a concentration of about 0.01 - 2% and more preferably 0.1 - 1%.
- licoricidin and licorisoflavan A are used as the antimicrobial agents in the body care products of the present invention they can be used alone or in a mixture at total concentrations of about 0.01 wt % to 1.0 wt %, at total concentrations of about 0.05 wt % to 0.5 wt % or at total concentrations of about 0.1 wt % to 0.2 wt %.
- the licorice extract used in the following examples and in the manufacture of dentifrices of the present invention was made with a novel and non-obvious supercritical CO 2 extraction process.
- the extraction process of the present invention was as follows. The root of Glycyrrhiza uralensis was cut, ground and powdered to create a raw material. The raw material was put into an extraction chamber (the extractor). The extraction chamber was fed with liquid CO 2 . The liquid CO 2 , brought from the working/storage tank, was cooled and pumped into the extraction chamber at 300 bar, 50 0 C with the 5 % addition of 96% ethanol. The CO 2 extract was then metered through an evaporator and flowed into a separation tank.
- CO 2 Under supercritical conditions established in the extractor, CO 2 has solvent properties for lipophilic ingredients whereas CO 2 in the gas phase is without solvent power under the conditions in the separator (60 bar, 30 0 C). Thus the extract was precipitated and the gas was regenerated in the separation tank. The CO 2 was then liquefied by passing through a condenser and recycled to the working tank.
- Broth microdilution minimum inhibitory concentration For anaerobes, 190 ⁇ L of sterile, pre-reduced Wilkins Chalgren (WC) anaerobe broth with 0.075 % cysteine were added to the first well of the test series in a 96 well plate, followed by 100 ⁇ L in each of four additional test wells. Ten ⁇ L of filter-sterilized stock solution of licorice CO 2 extract, prepared at 40 mg/mL in ethanol, was added to the first well of the series. Contents of the first well were mixed thoroughly and serially diluted (1 :1 ) with the remaining four wells in the series; 100 ⁇ L were discarded from the final well in the series.
- WC Wilkins Chalgren
- Suspensions of Porphyromanas gingivalis ATCC 33277 or Prevotella were added to the test wells in 100 ⁇ L quantities. Appropriate growth promotion and sterility controls were included. Plates were incubated at 37 0 C anaerobically, until turbidity in the growth control well was observed. The MIC (minimum inhibitory concentration) was recorded as the lowest concentration inhibiting growth of the test organism as viewed with the unaided eye.
- Streptococcus mutans ATCC 25175 was tested in similar fashion, with Tryptic Soy Broth (TSB) as the test medium and incubation of plates at 37 0 C with 5 % CO 2 .
- Staphylococcus aureus ATCC 6538 was tested using Tryptic Soy Broth (TSB) as the test medium and incubation of plates at 37 0 C.
- Aspergillus niger ATCC 16404 was tested, with Tryptic Soy Broth (TSB) as the test medium and incubated at room temperature (25 0 C).
- the supercritical licorice extract of the present invention (with ethanol) was able to inhibit the growth of S. mutans, a cariogenic bacteria, at a concentration of 12.5 ⁇ g/ml.
- the supercritical licorice extract of the present invention without ethanol was only tested to 31.25 ⁇ g/ml. See, Table 1A.
- Licoricidin and licorisoflavan A are two of the components of the supercritical CO 2 extract of the present invention. They both showed antimicrobial activity on Streptococcus mutans at 3.125 ⁇ g/ml, the principal causal agent of caries and against Prevotella intermedia at about 0.78 ⁇ g/ml and about 1.56 ⁇ g /ml and Porphyromanas gingivalis at 0.39 ⁇ g/ml and 1.56 ⁇ g/ml for licoricidin and licorisoflavan A, respectively, as shown in Table 1 B. Porphyromonas gingivalis and Prevotella sp are involved in periodontitis. These concentrations were the minimum inhibitory concentrations (MIC).
- MIC is defined by those skilled in the art as the lowest concentration of an antimicrobial agent that will inhibit the visible growth of a microorganism after overnight incubation. Minimum inhibitory concentrations are used by those skilled in the art to monitor the activity of new antimicrobial agents. Chlorhexidine is used here as a positive control and is frequently found as an antibacterial agent in, for example, mouthwash.
- Broth microdilution minimum inhibitory concentration was performed as follows. Ten ⁇ l_ of filter-sterilized stock solution of pure compound, licoricidin or licorisoflavan A, prepared at 1 mg/mL in ethanol, was added to the first well of the series. Contents of the first well were mixed thoroughly and serially diluted (1:1) with the remaining seven wells in the series; 100 ⁇ l_ were discarded from the final well in the series. Suspensions of Porphyromanas gingivalis ATCC 33277 or Prevotella. intermedia ATCC 25611, diluted to approximately 1 x 10 6 cfu (colony forming units) per ml_, were added to the test wells in 100 ⁇ l_ quantities.
- Results were recorded as the mode value from triplicate experiments vs. each bacterium.
- P. intermedia and P. gingivalis are gram negative bacteria involved in periodontitis. Streptococcus mutans is involved in caries formation. Both compounds were able to inhibit the growth of those 3 pathogenic bacteria.
- Biofilm formation and viability A 24 h culture of P. gingivalis (ATCC 33277) in Todd-Hewitt broth supplemented with hemin and vitamin K (THB-HK) was diluted in fresh broth medium to obtain an optical density at 655 nm (OD ⁇ ss) of 0.07. Samples (100 ⁇ l_) were added to the wells of a 96-well tissue culture plate containing 100 ⁇ l_ of serial dilutions (0 to 500 ⁇ g/mL) of sterile plant extracts in THB-HK. Control wells with no extract were also inoculated.
- gingivalis was prepared as above and treated with the plant fractions (0 to 250 ⁇ g/mL) for 2 h (anaerobiosis, 37 0 C) prior to adding 25 ⁇ L XTT/menadione. After 1 h at 37 C C, the absorbance at 490 nm (A490) was read using a microplate reader. The licorice extract of the present invention was able to inhibit the growth of P.gingivalis and also inhibit the formation of P. gingivalis. P.gingivalis was then unable to attach (anti-adherence).
- LPS preparations Aggregatibacter actinomycetemcomitans ATCC 29522 (syns; Actinobacillus actinomycetemcomitans) and P. gingivalis ATCC 33277 were grown in their appropriate culture media. LPS were isolated from these bacterial strains by a method routinely used in our laboratory.
- U937 cells (ATCC CRL-1593.2), a human monoblastic leukemia cell line, was cultivated at 37 0 C in a 5 % CO 2 atmosphere in RPMI-1640 supplemented with 10 % FBS and 100 ⁇ g/mL of penicillin-streptomycin (RPMI-FBS).
- Monocytes (2 x 10 5 cells/ml) were incubated in RPMI-10 % FBS containing 10 ng/ml of phorbol myristic acid (PMA) for 48 h to induce differentiation into adherent macrophage-like cells. Following the PMA treatment, the medium was replaced with fresh medium and the differentiated cells were incubated for an additional 24 h prior to use.
- PMA phorbol myristic acid
- Adherent macrophages were suspended in RPMI-10 % FBS and centrifuged at 200 x g for 8 min. They were washed and suspended in RPMI-10 % FBS at a density of 1 x 10 6 cells/ml and seeded in a 6 well-plate (2 x 10 6 cells/well in 2 ml) at 37 0 C in a 5 % CO 2 atmosphere.
- the macrophages were treated with the licorice extract at concentrations up to 250 ⁇ g/ml and incubated at 37 0 C in 5 % CO 2 for 2 h before stimulation with LPS at a final concentration of 1 ⁇ g/ml. After a 24 h incubation (37 0 C in 5 % CO 2 ), the culture medium supernatants were collected and stored at -20 0 C until used. Cells incubated in culture medium with or without licorice extract, but not stimulated with LPS, were used as controls.
- cytokine levels were determined using commercial enzyme-linked immunosorbent assay (ELISA) kits (R&D Systems, Minneapolis, MN, U.S.A.) were used to quantify IL-1 ⁇ , IL-6, IL-8, and TNF- ⁇ concentrations in the cell-free culture supernatants according to the manufacturer's protocols. The absorbance at 450 nm was read in a microplate reader with the wavelength correction set at 550 nm.
- ELISA enzyme-linked immunosorbent assay
- the extracts of the present invention caused a significant inhibition in vitro of interleukin 1 ⁇ , interleukin 8 and tumor necrosis ⁇ production by macrophages produced from a U937 cells, a human monoblastic leukemia cell line stimulated with LPS of Aggregatibacter actinomycetemcomitans at a concentration of 10 ⁇ g/ml and at 5 ⁇ g/ml for interleukin 6.
- Licorice extract caused a significant inhibition in vitro of interleukin 6, interleukin 8 and tumor necrosis factor- ⁇ (TNF- ⁇ ) production by macrophages stimulated with LPS of P. gingivalis at a concentration varying from 5 - 10 ⁇ g/ml.
- HPLC was performed on a Zorbax Eclipse XDB C-18 (Agilent Technologies, Santa Clara, CA) 250 x 4.6 mm Ld., 5 ⁇ m, with Zorbax C-18 Guard Column: (Cat. # HP 990967-902 and HP 820950-925).
- the results are presented in Figure 1.
- the first chromatogram (A) shows an extract with hot water and it contains only hydrophilic compounds. The peak eluting after 4.5 mi ⁇ is glycyrrhizic acid. According to the UV spectrum and the retention time, glycyrrhizic acid is only present in the hot water extract.
- the second chromatogram (B) is a 100% ethanol extract and the chromatogram (C) is an ethyl acetate extract, both are very similar in composition, with the exception that B contains more hydrophilic compounds (eluting between 0-4 min.).
- the major components of the CO 2 extract are licoricidin (1, eluting after 16.5 min) and licorisoflavan A (2, eluting after 21 min.), together with an unidentified flavonoid peak 3 around 18 min.
- the supercritical extract using ethanol (EtOH) as a modifier contains more hydrophilic compounds that the supercritical extract without modifier, and contains the highest amounts of licoricidin and licorisoflavan A .
- EtOH ethanol
- the CO 2 extract uses only a small percentage of ethanol (5-10%) to achieve a good balance of hydrophilic and lipophilic compounds.
- the licoricidin and licorisoflavan A are highly dominant.
- Licoricidin and licorisoflavan A were isolated from the supercritical CO 2 extract of the present invention as follows. A quantity of about 433 mg of licorice CO 2 /EtOH extract was submitted to medium pressure liquid chromatography (MPLC) with a B ⁇ chi C-600 MPLC system (B ⁇ chi Analytical, Flawil, Switzerland) using an ODS-based (Phenomenex Luna C-18(2), 100 A) stationary phase using acetonitrile- water (45:55) as solvent and a flow rate of 5 mL/min. Fraction 3 contained licoricidin (32.8 mg), and licorisoflavan A (21.5 mg) was obtained from fraction 7.
- MPLC medium pressure liquid chromatography
- the purity of licoricidin was about 89 % and the purity of licorisoflavan A was about 91 %.
- the term "isolated" in regards to the licoricidin and licorisoflavan A of the present invention includes purities of about 50 % or greater, about 60 % or greater, about 70 wt. % or greater, about 80 wt. % or greater, about 90 wt. % or greater, about 95 wt. % or greater or about 99 wt. % or greater.
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2008248272A AU2008248272B2 (en) | 2007-05-02 | 2008-05-01 | Liquorice extract antimicrobial and anti-inflammatory isolates |
BRPI0810774A BRPI0810774A2 (en) | 2007-05-02 | 2008-05-01 | oral care or body care composition. |
MX2009011869A MX2009011869A (en) | 2007-05-02 | 2008-05-01 | Liquorice extract antimicrobial and anti-inflammatory isolates. |
EP08767466.9A EP2150233B1 (en) | 2007-05-02 | 2008-05-01 | Liquorice extract antimicrobial and anti-inflammatory isolates |
JP2010506311A JP5438672B2 (en) | 2007-05-02 | 2008-05-01 | Antibacterial and anti-inflammatory isolates from licorice extract |
CN200880023333A CN101730521A (en) | 2007-05-02 | 2008-05-01 | Liquorice extract antimicrobial and anti-inflammatory isolates |
CA2685845A CA2685845C (en) | 2007-05-02 | 2008-05-01 | Liquorice extract antimicrobial and anti-inflammatory isolates |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/799,524 US8236360B2 (en) | 2007-05-02 | 2007-05-02 | Supercritical CO2 liquorice extract and products made there from |
US11/799,524 | 2007-05-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008137009A1 true WO2008137009A1 (en) | 2008-11-13 |
Family
ID=39939691
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/005578 WO2008137009A1 (en) | 2007-05-02 | 2008-05-01 | Liquorice extract antimicrobial and anti-inflammatory isolates |
Country Status (12)
Country | Link |
---|---|
US (1) | US8236360B2 (en) |
EP (1) | EP2150233B1 (en) |
JP (1) | JP5438672B2 (en) |
CN (1) | CN101730521A (en) |
AU (1) | AU2008248272B2 (en) |
BR (1) | BRPI0810774A2 (en) |
CA (1) | CA2685845C (en) |
CO (1) | CO6241096A2 (en) |
MX (1) | MX2009011869A (en) |
RU (1) | RU2423116C1 (en) |
SG (1) | SG180038A1 (en) |
WO (1) | WO2008137009A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8715625B1 (en) | 2010-05-10 | 2014-05-06 | The Clorox Company | Natural oral care compositions |
JP2015093848A (en) * | 2013-11-12 | 2015-05-18 | 丸善製薬株式会社 | Skin cosmetic and hair cosmetic |
RU2645070C2 (en) * | 2016-06-06 | 2018-02-15 | Федеральное государственное бюджетное учреждение науки Институт клеточного и внутриклеточного симбиоза Уральского отделения Российской академии наук | Method for antimicrobial peptides production from domestic chicken platelets |
CN108101923A (en) * | 2017-12-14 | 2018-06-01 | 中山大学 | A kind of process for separation and purification of glabridin monomer |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA013370B1 (en) * | 2009-05-15 | 2010-04-30 | Общество С Ограниченной Ответственностью "Вдс" | Formulation for prophylaxis of dental diseases |
JP5893324B2 (en) * | 2011-09-30 | 2016-03-23 | サンスター株式会社 | Methyl mercaptan inhibitor |
US20150374658A1 (en) * | 2012-09-07 | 2015-12-31 | BRAIN AG - Biotechnology Research and Information Network AG | Composition comprising licoricidine |
CN105806964A (en) * | 2014-12-30 | 2016-07-27 | 洛阳惠中兽药有限公司 | Method for detecting Acanthopanax senticosus and Glycyrrhiza uralensis preparation and application thereof |
WO2017049328A1 (en) * | 2015-09-16 | 2017-03-23 | Tshwane University Of Technology | A chewable gum composition |
EP3806686A4 (en) * | 2018-06-12 | 2022-03-23 | Buzzelet Development And Technologies Ltd | Dental care cannabis device and use thereof |
CN108743580B (en) * | 2018-07-31 | 2019-03-19 | 南京道尔医药科技有限公司 | Application of the Radix Glycyrrhizae isoflavan first in preparation medicament for treatment of depression |
CN109223663A (en) * | 2018-11-23 | 2019-01-18 | 丹东康齿灵牙膏有限公司 | A kind of Chinese herbal toothpaste and preparation method thereof for gingivitis |
BE1028259B1 (en) * | 2020-05-04 | 2021-12-07 | Dyna S A R L | Composition for strengthening and / or regulating the immune response |
CN113786399A (en) * | 2021-10-13 | 2021-12-14 | 吉林大学 | Application of glabridin in preparation of salmonella III type secretion system inhibitor |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4639466A (en) | 1984-10-01 | 1987-01-27 | Merck & Co., Inc. | 3',6-diisopentenyl-2',4'-dihydroxy-5,7-dimethoxy-isoflavan and related compounds useful as anxiolytic agents and avermectin antidotes |
EP1057825A1 (en) * | 1998-01-27 | 2000-12-06 | Shionogi & Co., Ltd. | Isoflavane derivatives and immunopotentiating compositions containing the same |
US6280780B1 (en) | 2000-08-24 | 2001-08-28 | Warner-Lambert Company | Method and apparatus for continuously forming coated center-filled gum products |
WO2002066041A1 (en) * | 2001-02-23 | 2002-08-29 | Herbal Detox Therapy Aps | Natural composition |
US6479043B1 (en) | 2000-10-04 | 2002-11-12 | Del Laboratories, Inc. | Depilatory composition |
US6586018B1 (en) | 2001-08-31 | 2003-07-01 | Sabina Fasano | Herbal composition |
US6861062B2 (en) | 2000-03-01 | 2005-03-01 | Victor Silva | Skin cream |
US20050048007A1 (en) * | 2000-11-02 | 2005-03-03 | Inobys Ltd. | Plaque reducing composition |
US20050119156A1 (en) * | 2001-12-19 | 2005-06-02 | Luca Turin | Aromachemicals |
US20050118289A1 (en) * | 2002-04-04 | 2005-06-02 | Kaneka Corporation | Process for producing fat composition containing hydrophobic components of glycyrrhiza |
US7179454B2 (en) | 2004-04-06 | 2007-02-20 | Sean A. Lucas | Personal care composition for shaving |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1849569A (en) * | 1929-08-26 | 1932-03-15 | Condorelli Pietro | Process for extracting the juice from liquorice |
GB457349A (en) | 1935-07-05 | 1936-11-26 | Yutaka Ito | Improvements in the manufacture of liquorice extract |
US3066072A (en) * | 1957-06-27 | 1962-11-27 | Biorex Laboratories Ltd | Extract from liquorice root having anti-inflammatory activities |
JPS5539671A (en) | 1978-09-14 | 1980-03-19 | Mitsubishi Electric Corp | Liquid coloring matter q-switching composition for neodymium laser |
US4176228A (en) * | 1978-09-14 | 1979-11-27 | Macandrews And Forbes Company | Potassium-magnesium-calcium glycyrrhizin |
JPS5615654A (en) | 1979-07-13 | 1981-02-14 | Kibun Kk | Food additive and its use |
US4545979A (en) * | 1982-02-22 | 1985-10-08 | Warner-Lambert Company | Dental hygiene compositions |
JPS60178815A (en) | 1984-02-24 | 1985-09-12 | Rikagaku Kenkyusho | Carcinostatic agent |
JPH01135723A (en) * | 1987-11-20 | 1989-05-29 | Idemitsu Petrochem Co Ltd | Extraction of antimicrobial substance in licorice |
JP2805325B2 (en) * | 1989-03-08 | 1998-09-30 | 丸善製薬株式会社 | Antioxidant |
JP2848688B2 (en) * | 1990-10-26 | 1999-01-20 | サンスター株式会社 | Oral composition |
JPH0648952A (en) * | 1992-07-31 | 1994-02-22 | Idemitsu Petrochem Co Ltd | Method for fractionating fat-soluble physiologically active substance |
US5496541C1 (en) * | 1993-01-19 | 2001-06-26 | Squigle Inc | Tasteful toothpaste and other dental products |
WO1996004807A1 (en) * | 1994-08-17 | 1996-02-22 | Wixon-Fontarome, Inc. | Process for a free-flowing food product |
FR2735477B1 (en) | 1995-06-14 | 1997-09-05 | Extraits Vegetaux Et Derives E | PROCESS FOR PROCESSING SLIP EXTRACTS |
RU2130733C1 (en) | 1998-05-06 | 1999-05-27 | Всероссийский научно-исследовательский институт консервной и овощесушильной промышленности | Method of producing licorice extract |
CN1136225C (en) | 2000-04-03 | 2004-01-28 | 孙传经 | Supercritical CO2 extraction method for extracting glycyrrhizinic acid from licorice |
US6319523B1 (en) * | 2000-06-29 | 2001-11-20 | James H. Zhou | Composition and method for inhibiting oral bacteria |
US6979471B1 (en) * | 2000-09-05 | 2005-12-27 | Council Of Scientific And Industrial Research | Composition comprising pharmaceutical/nutraceutical agent and a bio-enhancer obtained from Glycyrrhiza glabra |
IL138603A0 (en) * | 2000-09-21 | 2001-10-31 | Ready Made 37 1999 Ltd | Licorice extract for use as a medicament |
GB2368792A (en) * | 2000-10-06 | 2002-05-15 | Roger Randal Charles New | Absorption enhancers |
US7521079B2 (en) * | 2001-06-21 | 2009-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing an extract of Hydrangea containing plant powder |
US6986906B2 (en) * | 2001-09-25 | 2006-01-17 | Herbasway Laboratories, Llc | Cranberry based dietary supplement and dental hygiene product |
CA2460134A1 (en) * | 2001-10-11 | 2003-05-08 | Kaneka Corporation | Peroxisome proliferator activated receptor ligand and process for producing the same |
US7201930B2 (en) * | 2001-11-05 | 2007-04-10 | Haley Jeffrey T | Licorice root extract oral patch for treating canker sores |
JP3935346B2 (en) * | 2001-12-12 | 2007-06-20 | 三井農林株式会社 | Method for solubilizing licorice oil-based extract in aqueous system |
CN1359905A (en) | 2001-12-15 | 2002-07-24 | 宁夏大学 | Process for extracting licoflavone, lycyrrhizic acid and licopolyose from liquorice root |
TW200416037A (en) * | 2002-02-20 | 2004-09-01 | Kanegafuchi Chemical Ind | Process for producing hydrophobic glycyrrhiza extract with high qualities |
US20040115138A1 (en) * | 2002-04-19 | 2004-06-17 | Marissa Healy | Stable herbal dentifrice |
KR100530669B1 (en) | 2002-05-21 | 2005-11-23 | 주식회사 코리아나화장품 | Cosmetic Compositions Comprising Lactate and Glycyrrhiza Uralensis Extracts for Skin Whitening |
US20030228379A1 (en) * | 2002-05-28 | 2003-12-11 | Wenyuan Shi | Herbs and herbal combinations useful for the treatment of microbial infections |
US7288270B1 (en) * | 2002-05-30 | 2007-10-30 | Sekharam Kotha S | Therapeutic composition for the prevention and treatment of mucositis and mucosal disorders |
KR20050041390A (en) | 2003-10-30 | 2005-05-04 | 임교빈 | Extraction method of glycyrrhizic acid using supercritical fluid extraction |
US7351280B2 (en) * | 2004-02-10 | 2008-04-01 | New York University | Macroporous, resorbable and injectible calcium phosphate-based cements (MCPC) for bone repair, augmentation, regeneration, and osteoporosis treatment |
US7351739B2 (en) * | 2004-04-30 | 2008-04-01 | Wellgen, Inc. | Bioactive compounds and methods of uses thereof |
KR100669358B1 (en) | 2004-07-21 | 2007-01-15 | 송재홍 | Powder toothpaste containing far infrared ray emitting source |
KR20060098480A (en) * | 2005-03-03 | 2006-09-19 | 임교빈 | Formation of oil-soluble licorice extract including whitening bioactive materials |
US20060269494A1 (en) * | 2005-05-27 | 2006-11-30 | Gupta Shyam K | New Ubiquitin-Proteasome Regulating Compounds and Their Application in Cosmetic and Pharmaceutical Formulations |
US7736629B2 (en) * | 2005-11-18 | 2010-06-15 | Colgate-Palmolive Company | Red herbal dentifrice |
CN100404526C (en) | 2006-01-20 | 2008-07-23 | 华中科技大学 | Method for extracting glycyrrhizicacid, licorice flavone and licorice polysaccharide |
-
2007
- 2007-05-02 US US11/799,524 patent/US8236360B2/en active Active
-
2008
- 2008-05-01 MX MX2009011869A patent/MX2009011869A/en active IP Right Grant
- 2008-05-01 RU RU2009144535/15A patent/RU2423116C1/en not_active IP Right Cessation
- 2008-05-01 CA CA2685845A patent/CA2685845C/en not_active Expired - Fee Related
- 2008-05-01 CN CN200880023333A patent/CN101730521A/en active Pending
- 2008-05-01 SG SG2010077592A patent/SG180038A1/en unknown
- 2008-05-01 JP JP2010506311A patent/JP5438672B2/en not_active Expired - Fee Related
- 2008-05-01 EP EP08767466.9A patent/EP2150233B1/en not_active Not-in-force
- 2008-05-01 AU AU2008248272A patent/AU2008248272B2/en not_active Ceased
- 2008-05-01 BR BRPI0810774A patent/BRPI0810774A2/en not_active Application Discontinuation
- 2008-05-01 WO PCT/US2008/005578 patent/WO2008137009A1/en active Application Filing
-
2009
- 2009-12-02 CO CO09137860A patent/CO6241096A2/en not_active Application Discontinuation
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4639466A (en) | 1984-10-01 | 1987-01-27 | Merck & Co., Inc. | 3',6-diisopentenyl-2',4'-dihydroxy-5,7-dimethoxy-isoflavan and related compounds useful as anxiolytic agents and avermectin antidotes |
EP1057825A1 (en) * | 1998-01-27 | 2000-12-06 | Shionogi & Co., Ltd. | Isoflavane derivatives and immunopotentiating compositions containing the same |
US6861062B2 (en) | 2000-03-01 | 2005-03-01 | Victor Silva | Skin cream |
US6280780B1 (en) | 2000-08-24 | 2001-08-28 | Warner-Lambert Company | Method and apparatus for continuously forming coated center-filled gum products |
US6479043B1 (en) | 2000-10-04 | 2002-11-12 | Del Laboratories, Inc. | Depilatory composition |
US20050048007A1 (en) * | 2000-11-02 | 2005-03-03 | Inobys Ltd. | Plaque reducing composition |
WO2002066041A1 (en) * | 2001-02-23 | 2002-08-29 | Herbal Detox Therapy Aps | Natural composition |
US6586018B1 (en) | 2001-08-31 | 2003-07-01 | Sabina Fasano | Herbal composition |
US20050119156A1 (en) * | 2001-12-19 | 2005-06-02 | Luca Turin | Aromachemicals |
US20050118289A1 (en) * | 2002-04-04 | 2005-06-02 | Kaneka Corporation | Process for producing fat composition containing hydrophobic components of glycyrrhiza |
US7179454B2 (en) | 2004-04-06 | 2007-02-20 | Sean A. Lucas | Personal care composition for shaving |
Non-Patent Citations (3)
Title |
---|
JIAN HE ET AL., JOURNAL OF NATURAL PRODUCTS, vol. 69, no. 1, 2006, pages 121 - 124 |
See also references of EP2150233A1 * |
ZENG ET AL.: "Antibacterial Compounds from Glycyrrhiza uralensis", HETEROCYCLES: AN INTERNATIONAL JOURNAL FOR REVIEWS AND COMMUNICATIONS IN HETEROCYCLIC CHEMISTRY, vol. 34, no. 3, 1992, pages 575 - 587 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8715625B1 (en) | 2010-05-10 | 2014-05-06 | The Clorox Company | Natural oral care compositions |
JP2015093848A (en) * | 2013-11-12 | 2015-05-18 | 丸善製薬株式会社 | Skin cosmetic and hair cosmetic |
RU2645070C2 (en) * | 2016-06-06 | 2018-02-15 | Федеральное государственное бюджетное учреждение науки Институт клеточного и внутриклеточного симбиоза Уральского отделения Российской академии наук | Method for antimicrobial peptides production from domestic chicken platelets |
CN108101923A (en) * | 2017-12-14 | 2018-06-01 | 中山大学 | A kind of process for separation and purification of glabridin monomer |
CN108101923B (en) * | 2017-12-14 | 2020-07-31 | 中山大学 | Separation and purification method of glabridin monomer |
Also Published As
Publication number | Publication date |
---|---|
EP2150233A1 (en) | 2010-02-10 |
EP2150233A4 (en) | 2015-08-12 |
AU2008248272A1 (en) | 2008-11-13 |
RU2009144535A (en) | 2011-06-10 |
CN101730521A (en) | 2010-06-09 |
MX2009011869A (en) | 2010-02-24 |
JP2010526067A (en) | 2010-07-29 |
US20080274179A1 (en) | 2008-11-06 |
CO6241096A2 (en) | 2011-01-20 |
SG180038A1 (en) | 2012-05-30 |
JP5438672B2 (en) | 2014-03-12 |
AU2008248272B2 (en) | 2012-03-08 |
CA2685845A1 (en) | 2008-11-13 |
US8236360B2 (en) | 2012-08-07 |
EP2150233B1 (en) | 2018-07-11 |
BRPI0810774A2 (en) | 2015-09-15 |
CA2685845C (en) | 2014-07-29 |
RU2423116C1 (en) | 2011-07-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2685845C (en) | Liquorice extract antimicrobial and anti-inflammatory isolates | |
AU2005316974B2 (en) | Tartar control oral care composition containing extract of magnolia | |
TW200930414A (en) | Oral compositions containing botanical extracts | |
CA2906184A1 (en) | Polyphenol/flavonoid compositions and methods of formulating oral hygienic products | |
JPH11501918A (en) | Oral composition | |
EP2782550A2 (en) | An oral care composition comprising polyphenol | |
WO2017048617A1 (en) | Polyphenol/flavonoid compositions and methods of formulating oral hygienic products | |
US20080274063A1 (en) | Supercritical CO2 liquorice extract anti-microbial and anti-inflammatory isolates and products made there from | |
KR100307947B1 (en) | A method for preparation of plant extract powder and oral compositions containing plant extract powder prepared by the same | |
KR101216427B1 (en) | Calendula officinalis dentifrice composition and process for preparing the same | |
US8877266B2 (en) | Supercritical CO2 liquorice extract anti-microbial and anti-inflammatory isolates and products made there from | |
US20160074298A1 (en) | Polyphenol/flavonoid compositions and methods of formulating oral hygienic products | |
DE102010063720B4 (en) | Dental care composition containing silver | |
KR100951396B1 (en) | Dental composition for antiplaque and antigingivity | |
JP2019196329A (en) | Periodontal disease prevention oral composition | |
JP4145213B2 (en) | Oral composition | |
JP2004182649A (en) | Composition for oral cavity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200880023333.9 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08767466 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2685845 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 7021/DELNP/2009 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010506311 Country of ref document: JP Ref document number: 2008248272 Country of ref document: AU |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2009/011869 Country of ref document: MX Ref document number: 12009502085 Country of ref document: PH |
|
ENP | Entry into the national phase |
Ref document number: 2008248272 Country of ref document: AU Date of ref document: 20080501 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008767466 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009144535 Country of ref document: RU Ref document number: 09137860 Country of ref document: CO Ref document number: 13100118 Country of ref document: CO |
|
ENP | Entry into the national phase |
Ref document number: PI0810774 Country of ref document: BR Kind code of ref document: A2 Effective date: 20091030 |